# Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

Study · id `cardio:ct-nct06046196` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06046196](<https://clinicaltrials.gov/study/NCT06046196>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06046196

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

## Technical summary

Registry record NCT06046196. Randomized; no masking; primary purpose treatment. Start 2020-11-18 (actual); primary completion 2023-03-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 148 participants (enrolled count; ClinicalTrials.gov record NCT06046196, source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)
- Started: 2020-11-18 (actual) (ClinicalTrials.gov record NCT06046196, source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)
- Primary completion: 2023-03-09 (actual) (ClinicalTrials.gov record NCT06046196, source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)
- Completion: 2023-03-09 (actual) (ClinicalTrials.gov record NCT06046196, source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06046196, source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06046196-2023-09-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease
- Condition: Arterial Occlusive Diseases
- Condition: Intermittent Claudication
- Intervention (Drug): Sarpogrelate SR
- Intervention (Drug): Sarpogrelate
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: c103e169b4a203fac4dd7e210feeab6e7dfb46955032af368f32fb5913d6c0a7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
